Telo Genomics pioneers the most comprehensive 3-dimensional telomere analytics platform to assess risk of progression, treatment outcome or active monitoring of multiple myeloma patients and other cancers. TeloView®, the company’s ground-breaking single-cell analysis platform, utilizes a proprietary algorithm to quantify genomic disease signals enabling dynamic assessment of genomic changes and empowering precision medicine treatment decisions. TeloView technology is applicable to liquid biopsy.